Amylyx Pharmaceuticals, Inc. filings document a clinical-stage biotechnology issuer developing investigational therapies in endocrine conditions and neurodegenerative diseases. Its 8-K reports furnish quarterly and annual financial results, corporate presentations and material-event disclosures tied to programs such as avexitide for post-bariatric hypoglycemia, AMX0318 and AMX0035.
Proxy and material-event filings describe governance, executive compensation, shareholder voting matters, common-stock registration on the Nasdaq Global Select Market, capital-structure matters, material agreements and program decisions. These records also capture collaboration economics, development-candidate selections, expanded pipeline disclosures and formal updates to clinical programs.
Amylyx Pharmaceuticals ownership update: Perceptive Life Sciences Master Fund, Ltd. directly holds 8,284,882 shares of Common Stock, representing 7.5% of the class based on 111,186,317 shares outstanding as of April 27, 2026. Perceptive Advisors LLC is the investment manager and Joseph Edelman is the managing member; all three Reporting Persons report shared voting and dispositive power over the same 8,284,882 shares.
Amylyx Pharmaceuticals reported a larger net loss while advancing its endocrine and neurodegenerative pipeline in the first quarter of 2026. The company posted a net loss of $41.3 million, or $0.37 per share, compared with a net loss of $35.9 million, or $0.42 per share, a year earlier.
Research and development expenses rose to $27.6 million, mainly from increased spending on avexitide for post-bariatric hypoglycemia and $4.0 million in milestone payments tied to AMX0318. Cash, cash equivalents, and short-term investments were $279.8 million at March 31, 2026, which the company expects to fund operations into 2028.
Amylyx completed enrollment in its 78-participant Phase 3 LUCIDITY trial of avexitide in PBH and expects topline data in the third quarter of 2026, with a potential commercial launch in 2027 if approved. The company is also progressing the AMX0114 ALS program and preclinical candidate AMX0318.
Amylyx Pharmaceuticals, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 4, 2026 at 9:00 a.m. Eastern Time. The meeting will be held online via live webcast, allowing stockholders to vote and submit questions remotely.
Stockholders will vote on electing two Class II directors (George Mclean Milne Jr., Ph.D. and Paul Fonteyne) to terms ending in 2029, ratifying Deloitte & Touche LLP as independent auditor for 2026, and approving on an advisory basis the compensation of named executive officers. The proxy describes a board dominated by independent directors, four standing committees, and an executive pay program emphasizing at-risk bonuses and equity, including one-time performance stock units tied to key avexitide Phase 3 and FDA approval milestones. It also notes Deloitte audit fees of $862,500 for 2025 and outlines policies on clawbacks, hedging, and board nomination and governance.
Amylyx Pharmaceuticals Inc ownership disclosure: The Vanguard Group filed an amendment noting it beneficially owns 0 shares of Common Stock, representing 0% of the class.
The filing states Vanguard reorganized on January 12, 2026 and, in accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries will report separately and Vanguard no longer is deemed to beneficially own those securities.
Amylyx Pharmaceuticals furnished an updated corporate presentation outlining progress across its rare disease pipeline and financial position. The company highlighted completion of enrollment in the Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia, with topline data expected in Q3 2026 and a potential commercial launch in 2027 if approved.
The presentation also noted completion of enrollment in Cohort 2 of the Phase 1 LUMINA trial of AMX0114 for ALS, positive Phase 2 HELIOS results for AMX0035 in Wolfram syndrome, and nomination of AMX0318 as a long-acting GLP-1 receptor antagonist development candidate. As of December 31, 2025, Amylyx reported $317 million in cash, cash equivalents, and short-term investments and approximately 110 million shares outstanding, with a cash runway expected into 2028 through the potential approval and launch of avexitide in 2027.
Cohen Joshua B reported acquisition or exercise transactions in this Form 4 filing.
Amylyx Pharmaceuticals Co-Chief Executive Officer Joshua B. Cohen reported equity awards consisting of 248,865 shares of common stock from a restricted stock unit grant and a stock option covering 373,295 shares. The RSUs vest in four equal annual installments starting on March 1, 2027, while 25% of the option vests on that date and the remainder vests monthly over the following 36 months, all subject to his continued service.
Amylyx Pharmaceuticals Chief Legal Officer receives new equity awards. On March 5, 2026, Gina Mazzariello was granted stock options for 111,990 shares at an exercise price of $0.00 per share and an award of 74,660 shares of common stock in the form of restricted stock units.
The RSU award vests in four equal annual installments starting March 1, 2027, contingent on continued service. The stock option vests with 25% on March 1, 2027 and the remainder monthly over the next 36 months, also subject to continued service. Following these awards, she directly holds 209,090 shares of common stock.
Amylyx Pharmaceuticals Chief Financial Officer James M. Frates reported equity compensation awards in the form of stock options and restricted stock units. On March 5, 2026, he was granted stock options for 143,985 shares at an exercise price of $0.00 per share, and a separate grant of 95,990 shares of common stock as a restricted stock unit award.
The RSUs vest in four equal annual installments starting on March 1, 2027, subject to his continued service. Twenty‑five percent of the option vests on March 1, 2027, with the remainder vesting monthly over the following 36 months, also subject to continued service. Additional common shares are held indirectly by various family trusts for which he serves as trustee, and he disclaims beneficial ownership of those shares except to the extent of any pecuniary interest.